Form 4: Zevra CEO Sells Shares After RSU Vesting

Zevra Therapeutics CEO Neil F. McFarlane sold 14,625 shares of common stock following the vesting of 37,500 restricted stock units.

Summary

• Neil F. McFarlane, President and CEO of ZEVRA THERAPEUTICS, INC. (ZVRA), reported transactions involving the company's common stock.
• On February 7, 2026, 37,500 restricted stock units (RSUs) vested and settled into common stock.
• On February 9, 2026, McFarlane sold 14,625 shares of common stock at a weighted average price of $8.5597 per share.
• The sale was executed under a Rule 10b5-1(c) plan adopted on March 21, 2025.
• Following these transactions, McFarlane beneficially owns 387,225 shares of common stock directly and 75,000 restricted stock units directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction involving the vesting of equity compensation and a subsequent pre-planned sale, which is generally neutral in sentiment.

Positives

• The RSU vesting indicates a portion of the CEO's long-term incentive compensation has matured.
• The sale was conducted under a pre-arranged 10b5-1 plan, suggesting it was not based on new, non-public information.

Negatives

• A sale by a CEO, even if pre-planned, can sometimes be interpreted as a lack of confidence, though the amount sold is relatively small compared to total holdings.

Future Outlook

The remaining two-thirds of the restricted stock units (75,000 units) will vest and settle in two equal annual installments after February 7, 2026, contingent on the Reporting Person's continued service.

Management Comments

• The transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

StockSavvy.ai notes that insider sales, particularly by top executives, are routinely monitored by investors for signals regarding management's confidence. While this sale was pre-planned, it occurs within the context of the broader pharmaceutical and biotechnology industry, where executive compensation often includes equity components that lead to periodic sales for diversification or liquidity.

Comparison to Industry Standards

• StockSavvy.ai observes that sales by executives following RSU vesting are a common practice across industries, including pharmaceuticals, as part of managing personal finances and diversifying portfolios.
• The use of a 10b5-1 plan aligns with best practices for insider trading compliance, similar to executives at companies like Pfizer or Johnson & Johnson who often execute pre-scheduled sales of vested equity.

Stakeholder Impact

• Shareholders may observe the CEO's sale as a data point, but the pre-planned nature and context of RSU vesting suggest minimal direct impact on company operations or strategy.

Next Steps

• The remaining 75,000 restricted stock units held by Neil F. McFarlane will vest in two equal annual installments after February 7, 2026.

Key Dates

Recommendation

The filing details a routine insider transaction involving the vesting of restricted stock units and a subsequent pre-planned sale by the CEO. Such transactions are common and typically do not signal a fundamental change in the company's prospects or management's long-term view. Therefore, a 'hold' recommendation is appropriate as this specific filing does not provide new information warranting a change in investment thesis.

Keywords

Zevra Therapeutics, ZVRA, Neil F. McFarlane, Insider Trading, Form 4, Stock Sale, Restricted Stock Units, CEO, Biotechnology, Pharmaceuticals